Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment

Madhav Thambisetty, Yang An, Anna Kinsey, Deepthi Koka, Muzamil Saleem, Andreas Guntert, Michael Kraut, Luigi Ferrucci, Christos Davatzikos, Simon Lovestone, Susan M. Resnick

Research output: Contribution to journalArticle

Abstract

Recent genetic and proteomic studies demonstrate that clusterin/apolipoprotein-J is associated with risk, pathology, and progression of Alzheimer's disease (AD). Our main aim was to examine associations between plasma clusterin concentration and longitudinal changes in brain volume in normal aging and mild cognitive impairment (MCI). A secondary objective was to examine associations between peripheral concentration of clusterin and its concentration in the brain within regions that undergo neuropathological changes in AD. Non-demented individuals (N = 139; mean baseline age 70.5 years) received annual volumetric MRI (912 MRI scans in total) over a mean six-year interval. Sixteen participants (92 MRI scans in total) were diagnosed during the course of the study with amnestic MCI. Clusterin concentration was assayed by ELISA in plasma samples collected within a year of the baseline MRI. Mixed effects regression models investigated whether plasma clusterin concentration was associated with rates of brain atrophy for control and MCI groups and whether these associations differed between groups. In a separate autopsy sample of individuals with AD (N = 17) and healthy controls (N = 4), we examined the association between antemortem clusterin concentration in plasma and postmortem levels in the superior temporal gyrus, hippocampus and cerebellum. The associations of plasma clusterin concentration with rates of change in brain volume were significantly different between MCI and control groups in several volumes including whole brain, ventricular CSF, temporal gray matter as well as parahippocampal, superior temporal and cingulate gyri. Within the MCI but not control group, higher baseline concentration of plasma clusterin was associated with slower rates of brain atrophy in these regions. In the combined autopsy sample of AD and control cases, representing a range of severity in AD pathology, we observed a significant association between clusterin concentration in the plasma and that in the superior temporal gyrus. Our findings suggest that clusterin, a plasma protein with roles in amyloid clearance, complement inhibition and apoptosis, is associated with rate of brain atrophy in MCI. Furthermore, peripheral concentration of clusterin also appears to reflect its concentration within brain regions vulnerable to AD pathology. These findings in combination suggest an influence of this multi-functional protein on early stages of progression in AD pathology.

Original languageEnglish (US)
Pages (from-to)212-217
Number of pages6
JournalNeuroImage
Volume59
Issue number1
DOIs
StatePublished - Jan 2 2012

    Fingerprint

Keywords

  • Alzheimer's disease (26)
  • Atrophy
  • Biomarker
  • Clusterin
  • Mild cognitive impairment (MCI)
  • Plasma

ASJC Scopus subject areas

  • Neurology
  • Cognitive Neuroscience

Cite this

Thambisetty, M., An, Y., Kinsey, A., Koka, D., Saleem, M., Guntert, A., Kraut, M., Ferrucci, L., Davatzikos, C., Lovestone, S., & Resnick, S. M. (2012). Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. NeuroImage, 59(1), 212-217. https://doi.org/10.1016/j.neuroimage.2011.07.056